Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Tango Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Tango Therapeutics, Inc.’s stock price such as:

• Tango Therapeutics, Inc.’s current stock price and volume
• Why Tango Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for TNGX from analysts
• TNGX’s stock price momentum as measured by its relative strength

About Tango Therapeutics, Inc. (TNGX)

Before we jump into Tango Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Want to learn more about Tango Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Tango Therapeutics, Inc..

Tango Therapeutics, Inc.’s Stock Price as of Market Close

As of November 24, 2025, 4:00 PM, CST, Tango Therapeutics, Inc.’s stock price was $10.330.

Tango Therapeutics, Inc. is up 2.99% from its previous closing price of $10.030.

During the last market session, Tango Therapeutics, Inc.’s stock traded between $10.150 and $11.200. Currently, there are approximately 110.97 million shares outstanding for Tango Therapeutics, Inc..

Tango Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Tango Therapeutics, Inc. Stock Price History

Tango Therapeutics, Inc.’s (TNGX) price is currently up 27.37% so far this month.

During the month of November, Tango Therapeutics, Inc.’s stock price has reached a high of $11.200 and a low of $7.370.

Over the last year, Tango Therapeutics, Inc. has hit prices as high as $10.070 and as low as $1.030. Year to date, Tango Therapeutics, Inc.’s stock is up 234.3%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Tango Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 21, 2025, there was 1 analyst who downgraded Tango Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Tango Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Tango Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Tango Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Tango Therapeutics, Inc. (TNGX) by visiting AAII Stock Evaluator.

Relative Price Strength of Tango Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 21, 2025, Tango Therapeutics, Inc. has a weighted four-quarter relative price strength of 47.62%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Tango Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Tango Therapeutics, Inc. Stock Price: Bottom Line

As of November 24, 2025, Tango Therapeutics, Inc.’s stock price is $10.330, which is up 2.99% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Tango Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.